Subscribe to Newsletter
Diagnostics Genetics and epigenetics, Omics, Precision medicine, Regulation and standards

A Pharmacogenomic Promise

Pharmacogenomic testing is an increasingly significant part of many laboratory medicine professionals’ work. The more we learn about genes that affect drug efficacy, metabolism, or even the likelihood of adverse events, the more we can test to ensure that each patient receives the appropriate dose of the appropriate drug with the appropriate monitoring. However, not all tests are equal; some have a greater evidence base behind them or may simply be easier for clinicians or patients to understand. As a result, the Association for Molecular Pathology (AMP) has developed a set of best practices for clinical pharmacogenomic testing. We spoke to Jordan Laser, Medical Director of Long Island Jewish Medical Center – Pathology and Laboratory Medicine and Chair of AMP’s Professional Relations Committee, to learn more.

How is the rise in pharmacogenomic testing affecting pathologists and laboratory medicine professionals?

AMP members are among the early adopters of molecular diagnostic testing in clinical settings, and we are committed to improving professional practice and patient care. Our members have accumulated substantial knowledge and expertise that is useful for laboratories performing pharmacogenomictests, and our goal is to promote standardization of pharmacogenomic testing across clinical laboratories.

AMP continues to evaluate the evolving landscape of pharmacogenomic testing. As part of this evaluation, a group of leaders determined that clinically meaningful pharmacogenomic tests are poised to improve patient care and professional practice – provided that certain conditions are met. The set of conditions include:

  • All health-related pharmacogenomic claims must have well-established clinical validity.
  • The pharmacogenomic testing provider must comply with the Clinical Laboratory Improvement Amendments statute and regulations.
  • The pharmacogenomic test report should be easily understood by healthcare providers and include the interpretation of the findings, the significance of the results, and the limitations of the test.
  • Patients should not change their treatment plan without first talking to their healthcare provider.

What defines a clinically meaningful pharmacogenomic test?

Clinical pharmacogenomic tests are valuable tools that can help healthcare providers determine the optimal medication or treatment for a specific patient. As in all other practices of medicine, supporting clinical validity must be determined before the test is offered to patients. Evidence may be demonstrated through peer-reviewed literature, clinical practice guidelines, and/or FDA drug labels. One organization that develops clinical practice guidelines for pharmacogenomic testing is the Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC has developed a number of gene-drug practice guidelines to help determine a clinically meaningful test.

Patients gain the most benefit from pharmacogenomic testing when healthcare providers can easily determine when a patient’s genotype indicates an actionable treatment decision.

AMP encourages the use of such clinical practice guidelines. The AMP Pharmacogenetics (PGx) Working Group is also working on a series of evidence-based expert consensus opinion recommendations designed to help standardize alleles that should be included in clinical testing for frequently used genotyping assays. The Working Group started with CYP2C19 and CYP2C9 genotyping panels due to the widespread adoption of these tests and our desire to help physicians, pharmacists, researchers, and other stakeholders better understand what these panels include and what the test results mean.

We recognize that this is a quickly evolving field and that patients gain the most benefit from pharmacogenomic testing when healthcare providers can easily determine when a patient’s genotype indicates an actionable treatment decision. For this reason, AMP supports test reports that include the metabolizer status based on the genotype for the genes that affect drug metabolism; a list of the drugs for which responsiveness may be affected by the genotype; a generalized statement to alert healthcare providers when alternate dosage or drug treatment may be considered based on the results; and a list of resources and references that healthcare providers can use to learn more about the genotyping results.

What advice do you have on playing an active role in this testing?

We’re just beginning to realize the full potential of clinical pharmacogenomics in the era of precision medicine. These groundbreaking tests provide substantial benefits to patients when the drug-gene association is supported by strong scientific evidence and the healthcare provider is easily able to determine the actionable prescribing decision. Our new position statement on pharmacogenomic testing leverages our community’s collective expertise in this rapidly developing field and reflects AMP’s ongoing commitment to improving professional practice and patient care.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine